Aichetou Bouh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aichetou Bouh has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Daoud Daoudi
Mohammed V University in Rabat
7 shared publications - Souad Benaich
Mohammed V University
5 shared publications Nouriya El Ghoulam
Mohammed V University in Rabat, Faculty of Science, Department of Biology, Physiology and Physiopathology Research Team. 4, Avenue Ibn Batouta, Rabat, Morocco
4 shared publicationsSaber Boutayeb
Mohammed V University in Rabat
4 shared publications- Slimane Mehdad
Physiology and Physiopathology Research Team, Faculty of Sciences, Mohammed V University in Rabat, Morocco
4 shared publications - Ahmed Oubaasri
Mohammed V University in Rabat
3 shared publications
Latest Publications
- 10 July 2026
- Published by SAGE Publications in Mediterranean Journal of Nutrition and Metabolism
- Vol. 19 (4) , 310-324
Chemotherapy-associated changes in nutritional status, body composition, biochemical parameters, and physical activity among cancer patients: insights from a prospective cohort study
Background: Chemotherapy is often associated with metabolic and functional disorders that may affect treatment outcomes in cancer patients. This study aimed to assess chemotherapy-induced changes in weight, body composition, nutritional status, biochemical parameters, and physical activity levels in Moroccan cancer patients. Methods: This prospective cohort study involved 422 cancer patients treated by chemotherapy. Anthropometric measurements and bioelectrical impedance analysis were used to assess weight status and body composition. Nutritional status was evaluated using the Nutritional Risk Index, and biochemical parameters were obtained from the hospital's database. Physical activity levels were assessed by the International Physical Activity Questionnaire. Results: After chemotherapy, there were significant reduction in fat-free mass and increase in body fat percentage (P < 0.001). The proportion of patients with moderate/severe malnutrition, sarcopenic obesity, and low muscle mass increased from 34.2%, 29.1%, and 49.1% pre-treatment to 50.0%, 39.3%, and 57.8% post-treatment, respectively. There was a significant decrease in total protein levels ( P = 0.034). Physical activity and total energy expenditure decreased after chemotherapy (P < 0.001). Younger age (<60 years), low/moderate physical activity levels, and excessive body fat were independently associated with weight gain. Short disease duration (<12 months) and normal nutritional status were protective against moderate/severe weight loss, while non-excessive body fat increased such weight alteration. Non-malnourished patients and those without excess body fat had higher odds for low muscle mass. Conclusions: Chemotherapy induced significant alterations in weight, nutritional status, body composition, and physical activity. Early implementation of nutritional and lifestyle interventions is needed in oncological care to prevent treatment-related malnutrition and adverse outcomes in cancer patients.
- 10 July 2026
- Published by SAGE Publications in Mediterranean Journal of Nutrition and Metabolism
- Vol. 19 (4) , 310-324
Chemotherapy-associated changes in nutritional status, body composition, biochemical parameters, and physical activity among cancer patients: insights from a prospective cohort study
Background: Chemotherapy is often associated with metabolic and functional disorders that may affect treatment outcomes in cancer patients. This study aimed to assess chemotherapy-induced changes in weight, body composition, nutritional status, biochemical parameters, and physical activity levels in Moroccan cancer patients. Methods: This prospective cohort study involved 422 cancer patients treated by chemotherapy. Anthropometric measurements and bioelectrical impedance analysis were used to assess weight status and body composition. Nutritional status was evaluated using the Nutritional Risk Index, and biochemical parameters were obtained from the hospital's database. Physical activity levels were assessed by the International Physical Activity Questionnaire. Results: After chemotherapy, there were significant reduction in fat-free mass and increase in body fat percentage (P < 0.001). The proportion of patients with moderate/severe malnutrition, sarcopenic obesity, and low muscle mass increased from 34.2%, 29.1%, and 49.1% pre-treatment to 50.0%, 39.3%, and 57.8% post-treatment, respectively. There was a significant decrease in total protein levels ( P = 0.034). Physical activity and total energy expenditure decreased after chemotherapy (P < 0.001). Younger age (<60 years), low/moderate physical activity levels, and excessive body fat were independently associated with weight gain. Short disease duration (<12 months) and normal nutritional status were protective against moderate/severe weight loss, while non-excessive body fat increased such weight alteration. Non-malnourished patients and those without excess body fat had higher odds for low muscle mass. Conclusions: Chemotherapy induced significant alterations in weight, nutritional status, body composition, and physical activity. Early implementation of nutritional and lifestyle interventions is needed in oncological care to prevent treatment-related malnutrition and adverse outcomes in cancer patients.
- Open Access
- 27 June 2026
- Published by Society of Land Measurements and Cadastre from Transylvania in Notulae Scientia Biologicae
- Vol. 18 (2)
Moroccan Cannabis sativa L. seed chloroform extract: phytochemistry, acute toxicity, and metabolic-behavioral effects in mice
Despite growing interest in the therapeutic use of Cannabis sativa L. following its legalization for medicinal purposes in 2021, the toxicity profile of its seeds remains largely underexplored in Morocco. This study aimed to characterize the phytochemical profile and acute oral toxicity of a chloroform seed extract (C/S) from Moroccan Cannabis sativa L. C/S extract (yield: 4.27 ± 0.13%) was analyzed by gas chromatography coupled with mass spectrometry (GC-MS). Acute toxicity testing was performed according to OECD Test Guideline 425: female Swiss mice (n = 5/group) received a single 2,000 mg kg⁻¹ oral dose or vehicle control, followed by 14 d monitoring of clinical signs, body weight (BW), organ weight, and serum biochemistry (ASAT/ALAT, creatinine, urea, and lipid profile). GC-MS analysis revealed 16 compounds, with octacosane (6.80%), 2-methyloctadecane (5.75%), and cannabidiol (5.32%) as the major components. No treatment-related mortality was observed (LD₅₀ > 2,000 mg kg⁻¹), and only transient signs of hypoactivity/tachycardia were noted, which resolved spontaneously within a few hours. BW gain (p = 0.154), liver/BW (p = 0.103), and kidney/BW (p = 0.406) ratios showed no significant differences. Total cholesterol was lower in the C/S group than in controls (0.82 ± 0.06 g L⁻¹ vs. 2.13 ± 0.38 g L⁻¹, p = 0.014), whereas LDL-C was higher in the C/S group (0.07 ± 0.00 g L⁻¹ vs. 0.03 ± 0.01 g L⁻¹, p = 0.002). The C/S extract demonstrated low acute toxicity under the tested conditions, supporting further safety-oriented pharmaceutical investigation of Moroccan Cannabis sativa L. seeds.
- 27 June 2026
- Published by Society of Land Measurements and Cadastre from Transylvania in Notulae Scientia Biologicae
- Vol. 18 (2)
Open AccessMoroccan Cannabis sativa L. seed chloroform extract: phytochemistry, acute toxicity, and metabolic-behavioral effects in mice
Despite growing interest in the therapeutic use of Cannabis sativa L. following its legalization for medicinal purposes in 2021, the toxicity profile of its seeds remains largely underexplored in Morocco. This study aimed to characterize the phytochemical profile and acute oral toxicity of a chloroform seed extract (C/S) from Moroccan Cannabis sativa L. C/S extract (yield: 4.27 ± 0.13%) was analyzed by gas chromatography coupled with mass spectrometry (GC-MS). Acute toxicity testing was performed according to OECD Test Guideline 425: female Swiss mice (n = 5/group) received a single 2,000 mg kg⁻¹ oral dose or vehicle control, followed by 14 d monitoring of clinical signs, body weight (BW), organ weight, and serum biochemistry (ASAT/ALAT, creatinine, urea, and lipid profile). GC-MS analysis revealed 16 compounds, with octacosane (6.80%), 2-methyloctadecane (5.75%), and cannabidiol (5.32%) as the major components. No treatment-related mortality was observed (LD₅₀ > 2,000 mg kg⁻¹), and only transient signs of hypoactivity/tachycardia were noted, which resolved spontaneously within a few hours. BW gain (p = 0.154), liver/BW (p = 0.103), and kidney/BW (p = 0.406) ratios showed no significant differences. Total cholesterol was lower in the C/S group than in controls (0.82 ± 0.06 g L⁻¹ vs. 2.13 ± 0.38 g L⁻¹, p = 0.014), whereas LDL-C was higher in the C/S group (0.07 ± 0.00 g L⁻¹ vs. 0.03 ± 0.01 g L⁻¹, p = 0.002). The C/S extract demonstrated low acute toxicity under the tested conditions, supporting further safety-oriented pharmaceutical investigation of Moroccan Cannabis sativa L. seeds.
- Open Access
- 12 February 2026
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 38
Prevalence and correlates of metabolic syndrome in type 2 diabetes patients: A cross sectional study at the provincial diabetes center in Meknes, Morocco
- 12 February 2026
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 38
Open AccessPrevalence and correlates of metabolic syndrome in type 2 diabetes patients: A cross sectional study at the provincial diabetes center in Meknes, Morocco
- Open Access
- 12 December 2025
- Published by The North African Journal of Food and Nutrition Research (NAJFNR) in The North African Journal of Food and Nutrition Research
Nutritional Status, Muscle Mass, and Body Fat Percentage in Patients with Breast Cancer Undergoing Adjuvant Chemotherapy
Aims: To evaluate alterations in weight, body composition, and nutritional parameters, and to identify the clinical, anthropometric, and dietary determinants of these changes among patients with breast cancer (BC) treated with adjuvant chemotherapy (AC). Methods: This study involved a cohort of 252 BC patients treated with AC. Anthropometric measurements were collected using standardized equipment and body composition was evaluated via bioelectrical impedance analysis (BIA). Clinical data were retrieved from the hospital's information system. Adherence to the Mediterranean Diet (MedDiet) was evaluated using a validated food frequency questionnaire. Results: Post-AC, 29.3% and 22.7% of patients experienced moderate/high weight gain (WG ≥ 5%) and moderate/severe weight loss (MSWL ≥ 5%), respectively. The prevalence of patients with low muscle mass (LMM) and sarcopenic obesity increased from 11.5% and 2.8% pre-treatment to 15.1% and 7.9% post-treatment, respectively. Younger women (aged 24 – 39 years) exhibited reduced odds of experiencing MSWL (OR = 0.31, 95%CI: 0.08 – 1.20) and LMM (OR = 0.19, 95%CI: 0.02 – 1.61) compared to those aged ≥ 60 years. Patients with BC stages I and II were associated with increased odds of WG (OR = 2.10, 95%CI: 0.44 – 9.89; and OR = 2.13, 95%CI: 0.46 – 9.68, respectively). Relative to obese individuals, normal-weight/underweight individuals exhibited a significantly higher likelihood of WG (OR = 2.29; 95%CI: 1.03 – 5.08) and MSWL (OR = 3.23, 95%CI: 1.19 – 8.80), but a lower likelihood of LMM (OR = 0.33, 95%CI: 0.13 – 0.87). The Anthracycline-Taxane and Monoclonal-antibodies-Taxane regimens were associated with higher odds of MSWL (OR = 3.64, 95%CI: 0.35 – 36.98, and OR = 2.63, 95%CI: 1.03 – 6.72, respectively). Low and moderate adherence to the MedDiet were independently associated with an elevated risk of both WG and MSWL. Conclusions: A substantial proportion of patients with BC experience significant weight fluctuation or deterioration in muscle mass following AC. These adverse outcomes are modulated by patient age, cancer stage or duration, baseline BMI, the specific chemotherapy regimen employed, and MeDiet adherence. Keywords: Adjuvant chemotherapy; Body composition; Body Mass Index; Breast cancer; Mediterranean diet; Weight change.
- 12 December 2025
- Published by The North African Journal of Food and Nutrition Research (NAJFNR) in The North African Journal of Food and Nutrition Research
Open AccessNutritional Status, Muscle Mass, and Body Fat Percentage in Patients with Breast Cancer Undergoing Adjuvant Chemotherapy
Aims: To evaluate alterations in weight, body composition, and nutritional parameters, and to identify the clinical, anthropometric, and dietary determinants of these changes among patients with breast cancer (BC) treated with adjuvant chemotherapy (AC). Methods: This study involved a cohort of 252 BC patients treated with AC. Anthropometric measurements were collected using standardized equipment and body composition was evaluated via bioelectrical impedance analysis (BIA). Clinical data were retrieved from the hospital's information system. Adherence to the Mediterranean Diet (MedDiet) was evaluated using a validated food frequency questionnaire. Results: Post-AC, 29.3% and 22.7% of patients experienced moderate/high weight gain (WG ≥ 5%) and moderate/severe weight loss (MSWL ≥ 5%), respectively. The prevalence of patients with low muscle mass (LMM) and sarcopenic obesity increased from 11.5% and 2.8% pre-treatment to 15.1% and 7.9% post-treatment, respectively. Younger women (aged 24 – 39 years) exhibited reduced odds of experiencing MSWL (OR = 0.31, 95%CI: 0.08 – 1.20) and LMM (OR = 0.19, 95%CI: 0.02 – 1.61) compared to those aged ≥ 60 years. Patients with BC stages I and II were associated with increased odds of WG (OR = 2.10, 95%CI: 0.44 – 9.89; and OR = 2.13, 95%CI: 0.46 – 9.68, respectively). Relative to obese individuals, normal-weight/underweight individuals exhibited a significantly higher likelihood of WG (OR = 2.29; 95%CI: 1.03 – 5.08) and MSWL (OR = 3.23, 95%CI: 1.19 – 8.80), but a lower likelihood of LMM (OR = 0.33, 95%CI: 0.13 – 0.87). The Anthracycline-Taxane and Monoclonal-antibodies-Taxane regimens were associated with higher odds of MSWL (OR = 3.64, 95%CI: 0.35 – 36.98, and OR = 2.63, 95%CI: 1.03 – 6.72, respectively). Low and moderate adherence to the MedDiet were independently associated with an elevated risk of both WG and MSWL. Conclusions: A substantial proportion of patients with BC experience significant weight fluctuation or deterioration in muscle mass following AC. These adverse outcomes are modulated by patient age, cancer stage or duration, baseline BMI, the specific chemotherapy regimen employed, and MeDiet adherence. Keywords: Adjuvant chemotherapy; Body composition; Body Mass Index; Breast cancer; Mediterranean diet; Weight change.
- Open Access
- 26 June 2025
- Published by The North African Journal of Food and Nutrition Research (NAJFNR) in The North African Journal of Food and Nutrition Research
- Vol. 9 (20) , 310-322
Nutritional Status, Muscle Mass, and Body Fat Percentage in Patients with Breast Cancer Undergoing Adjuvant Chemotherapy
Aims: To evaluate alterations in weight, body composition, and nutritional parameters, and to identify the clinical, anthropometric, and dietary determinants of these changes among patients with breast cancer (BC) treated with adjuvant chemotherapy (AC). Methods: This study involved a cohort of 252 BC patients treated with AC. Anthropometric measurements were collected using standardized equipment and body composition was evaluated via bioelectrical impedance analysis (BIA). Clinical data were retrieved from the hospital's information system. Adherence to the Mediterranean Diet (MedDiet) was evaluated using a validated food frequency questionnaire. Results: Post-AC, 29.3% and 22.7% of patients experienced moderate/high weight gain (WG ≥ 5%) and moderate/severe weight loss (MSWL ≥ 5%), respectively. The prevalence of patients with low muscle mass (LMM) and sarcopenic obesity increased from 11.5% and 2.8% pre-treatment to 15.1% and 7.9% post-treatment, respectively. Younger women (aged 24 – 39 years) exhibited reduced odds of experiencing MSWL (OR = 0.31, 95%CI: 0.08 – 1.20) and LMM (OR = 0.19, 95%CI: 0.02 – 1.61) compared to those aged ≥ 60 years. Patients with BC stages I and II were associated with increased odds of WG (OR = 2.10, 95%CI: 0.44 – 9.89; and OR = 2.13, 95%CI: 0.46 – 9.68, respectively). Relative to obese individuals, normal-weight/underweight individuals exhibited a significantly higher likelihood of WG (OR = 2.29; 95%CI: 1.03 – 5.08) and MSWL (OR = 3.23, 95%CI: 1.19 – 8.80), but a lower likelihood of LMM (OR = 0.33, 95%CI: 0.13 – 0.87). The Anthracycline-Taxane and Monoclonal-antibodies-Taxane regimens were associated with higher odds of MSWL (OR = 3.64, 95%CI: 0.35 – 36.98, and OR = 2.63, 95%CI: 1.03 – 6.72, respectively). Low and moderate adherence to the MedDiet were independently associated with an elevated risk of both WG and MSWL. Conclusions: A substantial proportion of patients with BC experience significant weight fluctuation or deterioration in muscle mass following AC. These adverse outcomes are modulated by patient age, cancer stage or duration, baseline BMI, the specific chemotherapy regimen employed, and MeDiet adherence. Keywords: Adjuvant chemotherapy; Body composition; Body mass index; Breast cancer; Mediterranean diet; Weight change.
- 26 June 2025
- Published by The North African Journal of Food and Nutrition Research (NAJFNR) in The North African Journal of Food and Nutrition Research
- Vol. 9 (20) , 310-322
Open AccessNutritional Status, Muscle Mass, and Body Fat Percentage in Patients with Breast Cancer Undergoing Adjuvant Chemotherapy
Aims: To evaluate alterations in weight, body composition, and nutritional parameters, and to identify the clinical, anthropometric, and dietary determinants of these changes among patients with breast cancer (BC) treated with adjuvant chemotherapy (AC). Methods: This study involved a cohort of 252 BC patients treated with AC. Anthropometric measurements were collected using standardized equipment and body composition was evaluated via bioelectrical impedance analysis (BIA). Clinical data were retrieved from the hospital's information system. Adherence to the Mediterranean Diet (MedDiet) was evaluated using a validated food frequency questionnaire. Results: Post-AC, 29.3% and 22.7% of patients experienced moderate/high weight gain (WG ≥ 5%) and moderate/severe weight loss (MSWL ≥ 5%), respectively. The prevalence of patients with low muscle mass (LMM) and sarcopenic obesity increased from 11.5% and 2.8% pre-treatment to 15.1% and 7.9% post-treatment, respectively. Younger women (aged 24 – 39 years) exhibited reduced odds of experiencing MSWL (OR = 0.31, 95%CI: 0.08 – 1.20) and LMM (OR = 0.19, 95%CI: 0.02 – 1.61) compared to those aged ≥ 60 years. Patients with BC stages I and II were associated with increased odds of WG (OR = 2.10, 95%CI: 0.44 – 9.89; and OR = 2.13, 95%CI: 0.46 – 9.68, respectively). Relative to obese individuals, normal-weight/underweight individuals exhibited a significantly higher likelihood of WG (OR = 2.29; 95%CI: 1.03 – 5.08) and MSWL (OR = 3.23, 95%CI: 1.19 – 8.80), but a lower likelihood of LMM (OR = 0.33, 95%CI: 0.13 – 0.87). The Anthracycline-Taxane and Monoclonal-antibodies-Taxane regimens were associated with higher odds of MSWL (OR = 3.64, 95%CI: 0.35 – 36.98, and OR = 2.63, 95%CI: 1.03 – 6.72, respectively). Low and moderate adherence to the MedDiet were independently associated with an elevated risk of both WG and MSWL. Conclusions: A substantial proportion of patients with BC experience significant weight fluctuation or deterioration in muscle mass following AC. These adverse outcomes are modulated by patient age, cancer stage or duration, baseline BMI, the specific chemotherapy regimen employed, and MeDiet adherence. Keywords: Adjuvant chemotherapy; Body composition; Body mass index; Breast cancer; Mediterranean diet; Weight change.
- Open Access
- 10 May 2025
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 34
Exploring the relationships of Metabolic Syndrome with sociodemographic factors, weight status, dietary and lifestyle behaviors in Moroccan adults
- 10 May 2025
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 34
Open AccessExploring the relationships of Metabolic Syndrome with sociodemographic factors, weight status, dietary and lifestyle behaviors in Moroccan adults
- 24 April 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (7) , 1214-1228
The use of medicinal plants by cancer patients receiving chemotherapy: A cross-sectional study at a referral oncology hospital in Morocco
Background and aim: The high cost of cancer treatment and adverse side effects of drug therapy remain major health issues worldwide. Medicinal plants (MP) can be used to promote new, safe, and effective anticancer medications. This study aimed to estimate the prevalence of MP use among cancer patients, investigate its association with sociodemographic and clinical factors, and provide available information about the species used. Materials and methods: This was a cross-sectional study among 508 patients undergoing chemotherapy. Sociodemographic data and information on MPs used in cancer treatment were collected using face-to-face interviews and a questionnaire. Clinical data were obtained from the hospital database. Ethnobotanical indices, including relative citation frequency, informed consensus factor, and fidelity level, were determined for data analysis. Results: 43.2% of patients used MPs. Of these, 66.3% did not disclose information about MPs to their physicians, 54% experienced improvements, and 6% reported undesirable side effects associated with using MPs. There was a significant association of MPs use with disease duration ( P = 0.037) and cancer type ( P < 0.001). 27 plant species belonging to 17 families were identified, with Lamiaceae, Apiaceae, and Fabaceae being the most common. The most used species were Origanum compactum benth ., Marrubium vulgare L., Trigonella foenum-graecum L., Aloysia citriodora , and Rosmarinus officinalis L. Conclusion: This study showed a high prevalence of MPs use among patients undergoing chemotherapy. Although further studies are needed to investigate the efficacy and safety of commonly used species, our findings may be used to inform evidence-based guidelines, promote communication between cancer patients and healthcare providers, and develop new medicinal plants.
- 24 April 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (7) , 1214-1228
The use of medicinal plants by cancer patients receiving chemotherapy: A cross-sectional study at a referral oncology hospital in Morocco
Background and aim: The high cost of cancer treatment and adverse side effects of drug therapy remain major health issues worldwide. Medicinal plants (MP) can be used to promote new, safe, and effective anticancer medications. This study aimed to estimate the prevalence of MP use among cancer patients, investigate its association with sociodemographic and clinical factors, and provide available information about the species used. Materials and methods: This was a cross-sectional study among 508 patients undergoing chemotherapy. Sociodemographic data and information on MPs used in cancer treatment were collected using face-to-face interviews and a questionnaire. Clinical data were obtained from the hospital database. Ethnobotanical indices, including relative citation frequency, informed consensus factor, and fidelity level, were determined for data analysis. Results: 43.2% of patients used MPs. Of these, 66.3% did not disclose information about MPs to their physicians, 54% experienced improvements, and 6% reported undesirable side effects associated with using MPs. There was a significant association of MPs use with disease duration ( P = 0.037) and cancer type ( P < 0.001). 27 plant species belonging to 17 families were identified, with Lamiaceae, Apiaceae, and Fabaceae being the most common. The most used species were Origanum compactum benth ., Marrubium vulgare L., Trigonella foenum-graecum L., Aloysia citriodora , and Rosmarinus officinalis L. Conclusion: This study showed a high prevalence of MPs use among patients undergoing chemotherapy. Although further studies are needed to investigate the efficacy and safety of commonly used species, our findings may be used to inform evidence-based guidelines, promote communication between cancer patients and healthcare providers, and develop new medicinal plants.
- Open Access
- 28 August 2024
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 29
Epidemiological, clinical and evolutive profile of tuberculosis patients: Case of the region of Guelmim in Morocco
- 28 August 2024
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 29
Open AccessEpidemiological, clinical and evolutive profile of tuberculosis patients: Case of the region of Guelmim in Morocco